Pintó R M, González-Dankaart J F, Sánchez G, Guix S, Gómara M J, García M, Haro I, Bosch A
Department of Microbiology, University of Barcelona, Spain.
FEBS Lett. 1998 Oct 30;438(1-2):106-10. doi: 10.1016/s0014-5793(98)01278-2.
The immune responses elicited in mice by different forms of the VP3(110-121) B-epitope of the hepatitis A virus (HAV) were studied. Different forms of incorporation in liposomes were tested, encapsulation, rather than surface exposure, being the best antigenic preparation. Three larger peptides of the VP3 epitope, two of them containing a hepatitis B virus T-epitope, and a third containing a putative T-epitope of HAV (VP3(102-121)) were assayed. While this latter T-epitope induced an enhancement of the response against the VP3 B-epitope, the artificially coupled T-epitopes failed to induce a significant increase. The administration of two multiple antigenic peptide (MAP) constructs, the first containing the VP3(110-121) and VP1(11-25) HAV sequences and the second only the VP1(11-25) sequence, also suggested the presence of a T-epitope, since the response against the VP1 peptide was increased in the first construct.
研究了甲型肝炎病毒（HAV）VP3(110 - 121) B表位的不同形式在小鼠体内引发的免疫反应。测试了脂质体中不同的掺入形式，结果表明包封而非表面暴露是最佳的抗原制剂。检测了VP3表位的三种较大肽段，其中两种含有乙型肝炎病毒T表位，第三种含有假定的HAV T表位（VP3(102 - 121)）。虽然后一种T表位诱导了针对VP3 B表位的反应增强，但人工偶联的T表位未能诱导显著增加。两种多抗原肽（MAP）构建体的给药，第一种包含VP3(110 - 121)和VP1(11 - 25) HAV序列，第二种仅包含VP1(11 - 25)序列，这也表明存在T表位，因为在第一种构建体中针对VP1肽的反应增强了。
